Infinity Pharmaceuticals, (NASDAQ: [[ticker:INFI]]) a Cambridge, MA-based developer of cancer drugs, said today it has added two new members to its board, Martin Babler and Ian Smith. Babler is CEO of Talima Therapeutics, a privately-held drug delivery company in San Carlos, CA, and previously held senior marketing positions at Genentech (NYSE: [[ticker:DNA]]). Smith is chief financial officer of Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]). The company’s board now has 12 members, according to its web site.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
